SCHEMBL17836949

SCHEMBL17836949

CC(=O)Oc1cc2ncnc(Nc3ccccc3)c2cc1OC(C)=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 11/20 0.70
KDR P35968 8/20 0.70
RET P07949 3/20 0.70
LCK P06239 1/20 0.68
AURKA O14965 3/20 0.61
AURKB Q96GD4 3/20 0.61
MAPK14 Q16539 1/20 0.59
RIPK2 O43353 2/20 0.58
EPHB2 P29323 2/20 0.58
GAK O14976 1/20 0.56
STK10 O94804 1/20 0.56
FLT3 P36888 1/20 0.56
JAK3 P52333 1/20 0.56
AAK1 Q2M2I8 1/20 0.56
Q6ZSR9 Q6ZSR9 1/20 0.56
SLK Q9H2G2 1/20 0.56
IRAK4 Q9NWZ3 1/20 0.56
RPS6KA6 Q9UK32 1/20 0.56
ALK Q9UM73 1/20 0.56
FGFR1 P11362 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5240218 0.95 EGFR (0.79) EGFRKDRRETLCKAURKA
SCHEMBL13404528 0.92 EGFR (0.71) EGFRKDRRETLCKAURKA
SCHEMBL8809158 0.87 EGFR (0.67) EGFRKDRRETAURKAAURKB
SCHEMBL19885291 0.86 EGFR (0.65) EGFRKDRRETLCKAURKA
Hydrochloric Acid SCHEMBL3533953 0.84 AURKB (0.86) EGFRKDRAURKAAURKBMAPK14
SCHEMBL1999903 0.84 EGFR (0.74) EGFRKDRRETLCKAURKA
Hydrochloric Acid SCHEMBL28325957 0.84 AURKB (0.66) EGFRKDRRETLCKAURKA
SCHEMBL5144877 0.84 EGFR (0.70) EGFRKDRRET
SCHEMBL14964683 0.83 EGFR (0.80) EGFRKDRRETLCKRIPK2
SCHEMBL6688859 0.83 KDR (0.67) EGFRKDRRETLCKAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452220-B2 Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-09-27 US disclosed
US-20160175453-A1 COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-06-23 US disclosed
CN-103483275-B The coupling compound of NSAID class anti-inflammatory analgesic medicine and EGFR kinase inhibitor and synthetic method thereof and application GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2015-09-02 CN disclosed
CN-103483275-A Coupling compound of NSAID anti-inflammatory pain killers and EGFR kinase inhibitor and synthetic method and application of coupling compound GUANGZHOU INST BIOMED & HEALTH 2014-01-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160175453-A1 COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF EGFR, CHUK, ERBB2 EGFR 1/4885KDR 132/4885RET 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.